Assessment of the neuroprotective effects of a novel natural product derived formulation for the treatment of Parkinsons disease

“Parkinsons disease (PD) is a neurodegenerative disorder that affects approximately 1.5% of the global population over age 65. Current therapeutic interventions for PD are typically limited to attempts to correct the depletion of dopamine once motor symptoms become moderate to severe. Interventions with the potential to improve the cognitive function and quality of life of Parkinsons patients by modulating non-motor symptoms, as well as interventions with the potential to slow the rate of loss of dopaminergic neurons and to delay symptom emergence remain an unmet need. Neurodyn Life Sciences Inc. has developed a proprietary natural product-derived formulation of three bioactives with demonstrated neurosupportive and neuroprotective activity. The proposed project will continue the pre-clinical study of this novel formulation with the intent of progressing to clinical trials in human subjects with early stage PD.”

Faculty Supervisor:

Harold Robertson

Student:

Amber Marriott

Partner:

Neurodyn Inc.

Discipline:

Medicine

Sector:

Pharmaceuticals

University:

University of Prince Edward Island